abstract |
Combination of a PARP inhibitor selected from the group of tetracycline compounds, carboxamidobenzimidazole and 4-hydroxy-quinazoline, with an Akt kinase activating compound selected from the group of estrogen and resveratrol compounds, for use in the treatment of neurodegenerative disease. |